Oral Semaglutide Improves Cardiometabolic Metrics in Type 2 Diabetes

New data presented this week suggest the oral form of semaglutide, commonly known as Ozempic, offers broader health benefits than previously understood for individuals with type 2 diabetes and a heightened risk of cardiovascular disease. Beyond its established role in blood sugar management, the medication appears to positively influence several key cardiometabolic risk factors, including blood pressure and cholesterol levels.

The findings, stemming from a secondary analysis of the SOUL trial, indicate that adults receiving oral semaglutide experienced greater reductions in systolic and pulse blood pressure compared to those receiving a placebo. Improvements were also observed in triglyceride and total cholesterol levels. These results, published in JAMA Cardiology, add to a growing body of evidence supporting the potential of semaglutide to mitigate cardiovascular risk in a vulnerable patient population.

Beyond Blood Sugar: A Broader Impact on Cardiometabolic Health

For years, medications like semaglutide have been primarily recognized for their efficacy in controlling blood glucose levels in individuals with type 2 diabetes. However, the increasing recognition of the interconnectedness between diabetes, cardiovascular disease, and other metabolic disorders has prompted researchers to investigate the broader effects of these drugs. This latest analysis focuses specifically on cardiometabolic risk factors – those elements known to contribute to the development of heart disease, and stroke.

The SOUL trial, which included nearly 10,000 participants aged 50 and older with type 2 diabetes and established cardiovascular risk factors, provides a robust dataset for this type of investigation. Participants were randomly assigned to receive either oral semaglutide or a placebo, in addition to their standard care. Researchers tracked changes in various cardiometabolic markers over a period of up to 156 weeks.

According to Dr. Sharon L. Mulvagh, a professor of medicine at Dalhousie University and professor emeritus at Mayo Clinic, the observed benefits were particularly noteworthy because they appeared relatively early in the trial – as soon as 13 weeks – suggesting a direct effect of the drug beyond its impact on HbA1c (a measure of long-term blood sugar control) and weight loss. Dr. Mulvagh emphasized that these findings challenge the conventional assumption that improvements in cardiovascular risk factors are solely a consequence of weight reduction.

Specific Improvements Observed in the Trial

The analysis revealed several statistically significant differences between the semaglutide and placebo groups. Specifically, individuals taking semaglutide experienced an average decline in systolic blood pressure of 3.19 mm Hg greater than those taking the placebo after 13 weeks (P < .001). While changes in diastolic blood pressure weren’t significantly different between the groups, pulse pressure – the difference between systolic and diastolic pressure – decreased by an average of 3.7 mm Hg more in the semaglutide group (P < .001). These differences persisted, though slightly diminished, at the 156-week mark.

Improvements extended to lipid profiles as well. The semaglutide group demonstrated larger decreases in total cholesterol, non-HDL cholesterol, and triglycerides at both 13 and 156 weeks compared to the placebo group. Interestingly, HDL cholesterol (often referred to as “great” cholesterol) was initially lower in the semaglutide group at 13 weeks, but higher at 156 weeks. LDL cholesterol (“bad” cholesterol) was lower in the semaglutide group at 13 weeks, but this difference disappeared by the 156-week assessment.

Alongside these cardiometabolic improvements, the trial continued to demonstrate the drug’s effectiveness in managing blood sugar and promoting weight loss. Semaglutide recipients experienced a 0.82 percentage point greater decrease in HbA1c and a 2.28 percentage point larger decline in body weight compared to the placebo group at 13 weeks. These benefits were sustained, though slightly reduced, at 156 weeks.

Understanding the Implications and Limitations

These findings contribute to a growing understanding of the pleiotropic effects of GLP-1 agonists like semaglutide – meaning they exert effects beyond their primary target. While the exact mechanisms underlying these cardiovascular benefits are still being investigated, researchers believe they may involve direct effects on blood vessels, inflammation, and other pathways independent of weight loss or blood sugar control. Semaglutide, marketed under various brand names including Ozempic, Wegovy, and Rybelsus, works by mimicking the effects of glucagon-like peptide-1 (GLP-1), a natural hormone that regulates appetite and insulin secretion.

It’s important to note that this analysis is a secondary investigation of an existing trial, and therefore cannot definitively prove a causal relationship between semaglutide and the observed cardiometabolic benefits. As Dr. Mulvagh points out, a prospective study specifically designed to assess the impact of oral semaglutide on cardiovascular risk factors is needed to confirm these findings. The study population was limited to individuals with established cardiovascular risk factors, so the results may not be generalizable to all individuals with type 2 diabetes.

Regulatory Scrutiny and Ongoing Monitoring

The positive findings regarding semaglutide’s cardiovascular benefits come amidst increased regulatory scrutiny of Novo Nordisk, the drug’s manufacturer. The Food and Drug Administration (FDA) recently issued a warning letter to Novo Nordisk on March 5, detailing violations of postmarketing adverse drug experience regulations. The FDA’s concerns centered on failures to properly report adverse events, including instances where patient identifiers were missing or medical reviews were delayed. Novo Nordisk has stated it is working to address these concerns.

This regulatory action underscores the importance of ongoing monitoring and vigilance regarding the safety and efficacy of all medications, even those with promising benefits. The FDA’s postmarketing surveillance system plays a crucial role in identifying and addressing potential risks that may not have been apparent during clinical trials.

The Evolving Landscape of Cardio-Kidney-Metabolic Syndrome Management

Dr. Mulvagh believes the findings support a broader shift in how we approach the management of cardio-kidney-metabolic syndrome – a cluster of conditions that significantly increase the risk of cardiovascular disease and kidney failure. She argues that medications like semaglutide should be considered not just as glucose-lowering agents, but as potential tools for comprehensive cardiovascular risk reduction.

“Having an oral therapeutic option may be more favorable to some patients,” Dr. Mulvagh noted. The availability of an oral formulation of semaglutide expands access to this medication for individuals who may prefer a pill over an injection.

Looking ahead, further research is needed to fully elucidate the mechanisms underlying semaglutide’s cardiovascular benefits and to identify which patients are most likely to benefit from this therapy. Continued monitoring of long-term outcomes and adherence to robust postmarketing surveillance practices will be essential to ensure the safe and effective use of this increasingly important medication.